INTRODUCTION
Tolerance is usually defined as a reduction in the effects for the drug in question such that a higher dose (or blood concentration) of the drug is required to produce the same degree of effects as seen previously in the drug-naive individual. Tolerance is a complex phenomenon that develops as a result of adaptation of the organism to the presence of drugs in certain circumstances and can develop to different drug effects at different rates (28, 33, 39, 40, 100) . Investigators are interested in studying tolerance for multiple reasons, ranging from its role in addiction to neuroadaptation or neuronal plasticity (for details, see 38, 39, 64) .
Tolerance can develop and be measured within three different time frames. The most commonly studied form of tolerance, called chronic tolerance, increases gradually over days or weeks of drug administration. It usually includes both functional and dispositional components. Acute tolerance differs from chronic tolerance in that the former develops within a single exposure to the drug. The fact that such tolerance is seen even when the drug effect is related directly to the concentration in the brain (66) makes it clear that acute tolerance is indeed functional in nature. Another form, called rapid tolerance, is seen as a reduction in response to a second dose of drug that is given 8-24 h after the effect of the first dose has disappeared. Rapid tolerance is functional rather than dispositional. Although the existence of rapid tolerance has been known for nearly 20 years, its relationship to chronic tolerance has not been studied systematically until recently (38, 51) . Recent experiments indicate that rapid tolerance and chronic tolerance are closely related and suggest possible similarities between the mechanisms of rapid and chronic tolerance (44) . Both rapid tolerance and chronic tolerance have been shown to be influenced by, or to require, processes related to learning and memory. However, no similar comparison of acute tolerance with the other two forms has yet been carried out. Therefore, the nature of the relationship among these three time courses of tolerance and the question of whether they rest upon the same or different mechanisms is not clear.
In this review, we would not attempt to provide coverage of tolerance as there have been many excellent reviews of different aspects of this topic in the past two decades (28, 33, (38) (39) (40) 64, 100) . Rather, we will focus mainly on the possible role of the NMDA (N-methyl-D-aspartate) receptor system in rapid and chronic tolerance to some psychoactive drugs. Several drug classes, including ethanol, barbiturates, opiates and psychostimulants will be examined, since tolerance is a predominant phenomenon with these drug classes. We will first provide a general background on the NMDA receptor system. This will then be followed by some of the work that has been carried out on the effects of acute and chronic administration of ethanol on glutamate receptors. Then we will describe the influence of NMDA antagonists on tolerance to drugs with emphasis on ethanol tolerance, followed by the discussion on the participation of this system in tolerance to the effects of benzodiazepines, barbiturates and opioids.
GLUTAMATE AND NMDA RECEPTOR
Glutamate, the predominant excitatory neurotransmitter in the vertebrate central nervous system (CNS), is believed to activate three main receptor subtypes: NMDA ionotropic receptors; non-NMDA ionotropic receptors, and the metabotropic receptors. The ionotropic receptors contain cation-specific ion channels that allow the passage of Na + , K + , and Ca 2+ , whereas the metabotropic receptors are coupled to G proteins. The non-NMDA receptors, include α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainate (KA) receptors (2, 34) .
At present, the NMDA receptor subtype is the best characterized of the glutamate receptor subtypes. A detailed description of NMDA receptor is available in several studies (36, 76, 81) . This ionotropic receptor that controls the opening of a cation channel, has multiple modulatory sites. There are a transmitter recognition site, sensitive to glutamate and the allosteric modulatory site, sensitive to glycine, but insensitive to strychnine. Glycine has long been considered as the endogenous co-agonist of glutamate (78) . Two distinct sites for divalent cations (Mg 2+ and Zn 2+ ) also modulate the functioning of the receptor. Drugs such as phencyclidine, ketamine, and MK-801 (dizocilpine) act as non-competitive antagonists of NMDA receptor, blocking this receptor-gated ion channel (1, 108, 113) . Extracellular Mg 2+ ions cause voltage-dependent blockade of the channel. At the resting phase of neuron activity the channel is blocked by Mg 2+ . A slight depolarization of the neuron is enough to ensure that Mg 2+ leaves the channel allowing the transit of cations, mainly the influx of Ca 2+ . Other modulatory sites in the NMDA receptor may be influenced by polyamines, hydrogen ions and nitric oxide (88, 112) . The final effect of the NMDA-receptor simulation depends on the modulation of all these binding sites.
The NMDA receptor has been implicated in several functions including excitability, neurotoxicity, synaptic plasticity such as induction of long-term potentiation (LTP), and modulation of learning and memory (12, 15, 78, 80, 103) . The phenomenon of LTP, as a substrate for certain types of memory, has been found in most excitatory pathways, especially in the hippocampus (88) . Recently, molecular and cellular biology studies have shown that glutamate receptors are also involved in cortical plasticity (37) . Facilitation of glutamatergic transmission causes a general improvement in memory (95) , while dysfunction of glutamatergic pathways has been implicated in several CNS disorders (77) . Other studies have shown that NMDA system can be involved in the mechanisms related to the development of tolerance to several groups of drugs including ethanol, benzodiazepines, morphine and cocaine (18, (45) (46) (47) 49, 50, (53) (54) (55) (56) (57) (58) (59) (60) 105) . These studies with NMDA re-ceptor ligands have strengthened the notion that learning is involved in the development of tolerance to some psychoactive drugs (11, (45) (46) (47) 49, 50, (53) (54) (55) (56) (57) (58) (59) (60) .
NMDA AND ETHANOL TOLERANCE
For many years, ethanol, barbiturates and other sedative hypnotic and anesthetic agents were thought to exert their actions by a common nonspecific interaction with the lipid matrix of the cell membrane by expanding it. It was postulated that fluidization of the bulk lipid phase of the cell membrane was also responsible for the resistance to the cellular and physiological effects of these drugs in the tolerant animal (26, 90) . Recent research supports the view that these drugs exert their actions more selectively than previously thought and fluidizing effect disrupts the functions of some protein molecules and not others, i.e., each of these drugs could be quite selective in their effect on neurotransmitter receptors, ion channels and neurotransmitter receptors (38, 52) . For example, two receptor systems with high sensitivity to ethanol are NMDA and γ-aminobutyric acid (GABA) although 5-hydroxytryptamine (5-HT), dopamine, adenosine receptors and other neurotransmitter systems are also affected by ethanol (19, 48, 79, 82, 101, 107) .
In vitro studies have demonstrated that ethanol acutely inhibits NMDA functions (16, 67, 85) , but chronic administration of ethanol may result in increased activity of this system (16, 23, 31) . Behavioral studies provide additional support for the involvement of the NMDA receptor system in many of the actions of alcohol. D-cycloserine (DCS), a partial agonist at the glycine site of the NMDA receptor, blocked the anxiolytic effect of ethanol in rats tested in the elevated plus-maze (21) . The anxiolytic effect produced by HA-966 [(±)-3-amino-1-hydroxy-2-pyrrolidone], a drug acting as an antagonist at the glycine site in NMDA receptor, was similarly blocked by previous treatment with DCS, suggesting that ethanol and HA-966 may share similar mechanisms of anxiolytic action (20) .
Since the NMDA receptor system is involved in processes underlying learning and memory, and since both rapid tolerance and chronic tolerance have been shown to be influenced by, or to be related to, processes linked to learning and memory (40, 94) , we hypothesized that the acquisition of ethanol tolerance should similarly be subject to interference by NMDA antagonists. Therefore, we tested whether the (+) and the (-)MK-801 isomers were able to interfere with rapid tolerance (60) . Both forms of the drug were given on day 1, at 30 min before the ethanol administration, and the animals were tested 24 h later with a challenge dose of ethanol. We observed that the (+)MK-801 isomer clearly blocked rapid tolerance to ethanol-induced motor incoordination and hypothermia, while the inactive isomer (-)MK-801 was ineffective. These effects were most likely mediated via a pharmacodynamic action since (±)MK-801 failed to modify blood ethanol concentrations. The generality of the inhibitory influence of NMDA antagonist on rapid tolerance was investigated in mice tested in the rotarod apparatus. The same dose range of (+)MK-801 and ketamine that can disrupt learning (41, 109) blocked rapid tolerance in a dose-dependent way, while (-)MK-801 did not have any effect (5) . These experiments suggest that the antagonism of tolerance by (+) and (-) isomers is stereospecific, and also gave support to the hypothesis that the role of NMDA receptors in ethanol tolerance could be similar to their role in learning and memory. Studies with more selective NMDA blockers that have less effects on learning and memory may help us to confirm this interpretation.
Further investigations were carried out to determine the duration of the inhibitory effect of MK-801 on the development of rapid tolerance. The results showed that the NMDA antagonist inhibited the development of tolerance from 2 to 5 d after the first ethanol administration (i.e., as long as rapid tolerance persisted), but not thereafter when no rapid tolerance was present. Moreover, the blockade of rapid tolerance by MK-801 and ketamine (another commonly employed noncompetitive NMDA antagonist) was observed only when the NMDA antagonists were given before the behavioral testing with ethanol, but not when they were injected after the test with ethanol (50, 56) . These experiments suggest that NMDA antagonists may be influencing some adaptive process that occur during the testing phase. We hypothesized that the blockade of acquisition of rapid tolerance by MK-801 and ketamine could be related to the prevention of the learning that took place during the intoxicated practice on day one, but had no effect once the consolidation of the learning had already occurred before the antagonists were given.
To further investigate the hypothesis that the blockade of tolerance and the prevention of learning by NMDA antagonists were related, Szabó et al. (99) compared the effects of MK-801 on tolerance to ethanol using two different protocols, where environment-dependent and environment-independent forms of tolerance to the effects of ethanol could be studied in mice. The authors found and that the NMDA receptor antagonist blocked only the associative or environment-dependent but not environment independent (non associative) ethanol tolerance. Similar results were obtained in a study using rats tested in the tilt-plane. In these experiments increasing doses of ketamine blocked the development of chronic tolerance to ethanol only when the animals practiced under the influence of ethanol (56) .
In another recent study (58), we compared the development of rapid tolerance in two different groups of rats: 1) in rats that were tested on the tilt-plane at all test times (intoxicated group), and 2) in rats that were not tested on the tilt-plane but were otherwise similarly handled on the first day of experiment (dummy testing). Both groups of animals were injected with ethanol on day 1 and they developed tolerance when tested on the next day. However, doses of MK-801 or ketamine given on day 1, which completely blocked rapid tolerance in the intoxicated practice paradigm, failed to block rapid tolerance in the dummy testing paradigm. Since rapid tolerance in the testing group is mainly learned intoxicated practice tolerance, these results suggest that NMDA antagonists will block only practice learned tolerance.
Wu et al. (115) and Karcz-Kubicha and Liljequist (42) have essentially confirmed the inhibition of tolerance to ethanol by NMDA antagonists. However, Wu et al. (115) reported impairment of tolerance to ethanol in both the practice and non-practice groups, whereas Karcz-Kubicha and Liljequist (42) reported that NMDA antagonists were effective in blocking ethanol tolerance even when administered after ethanol. The difference in the tests used for measuring tolerance, the degree of intoxication in the non-practice vs. practice group and the dose of the NMDA antagonist used may have resulted in a different outcome in these two studies.
NMDA antagonists have complex effects on behavior depending on the dose employed. Their interactions with hypnotics, sedatives or other drugs are quite variable. However, it appears that the blockade of tolerance cannot be attributed to such interactions. to motor impairment and hypothermic effects of ethanol, but its effect on tolerance was the same in both tests.
It is noteworthy that the blockade of rapid tolerance to ethanol by the NMDA antagonists was also observed when tolerance was enhanced by pretreatment of animals with different doses of D-cycloserine, a partial agonist at NMDA receptors (49, 54) . This finding suggests that the cellular mechanisms underlying rapid tolerance to ethanol can be modulated by drugs acting as either agonists or antagonists at the same receptor system. An interaction between different neurotransmitter systems can also explain the modulation of ethanol tolerance. For example, treatment with L-tryptophan, that results in increased serotonergic activity stimulated ethanol rapid tolerance as was shown previously for chronic tolerance (62, 63) . The increased tolerance caused by pretreatment with 5-hydroxytryptophan was blocked by pretreatment with MK-801 in a dose-response fashion (47) suggesting that the NMDA system is involved in some way in the serotonergic modulation of the acquisition of ethanol tolerance.
Recently, nitric oxide (NO), a compound synthesized from L-arginine residues by nitric oxide synthase (NOS), has been considered as a neuronal messenger. It has been suggested that NO synthesized at the postsynaptic level may serve as the retrograde messenger to the presynaptic neurons in the expression of long term potentiation (LTP) induced by activation of postsynaptic NMDA receptors (93) . Moreover, NO is reported to play a role in the acquisition of learning, since rats treated with an NO synthase inhibitor showed an impairment in some learning tasks (14) . To test whether NO could be involved in rapid tolerance, rats were treated with the inhibitor of NO synthesis, L-nitroarginine (L-NA), prior to ethanol administration, and on the next day they were submitted to a challenge dose of ethanol. The results showed that the blockade of NO synthase resulted in the blockade of tolerance (57) . The fact that D-NA, an inactive isomer, did not block rapid tolerance, but an excess of the substrate L-arginine reversed the inhibitory effect of L-NA on tolerance development suggests that NO is involved in the development of tolerance. This blockade of tolerance was also evident when tolerance was stimulated by D-cycloserine administered before ethanol at a dose that did not produce tolerance when given alone (55) .
NMDA AND BENZODIAZEPINE TOLERANCE
NMDA antagonists have been shown to interfere with tolerance to benzodiazepines. Pretreatment with either MK-801 or ketamine blocked tolerance to chlordiazepoxide-induced motor impairment in rats tested on the tilt plane test, but this effect was dependent on the dose ratio of the NMDA antagonist to that of the benzodiazepine (45) . Thus, this blockade was observed only when relatively low doses of chlordiazepoxide were used. When a higher dose of this drug was used, MK-801 or ketamine failed to block chlordiazepoxide tolerance. This study agrees with previous data demonstrating that NMDA antagonists blocked cross-tolerance between chlordiazepoxide and ethanol in either direction (53) . The effect of NMDA antagonists on tolerance to benzodiazepines was also observed in other studies. File and Fernandes (22) , reported that pretreatment with MK-801 blocked tolerance to the decrease in the number of head dips, and probably to the decrease in ambulation produced by diazepam in rats tested in the hole-board apparatus. The development of tolerance to the locomotor activity reduction induced by diazepam in mice was prevented by treatment with the NMDA antagonist CPP [(3-((±)-2-carboxypiperazin-4-yl)propyl-1-phosphonic acid)] (97).
As mentioned before, tolerance may have learned and unlearned components. Although some studies have shown that NMDA antagonists preferentially block learned tolerance to ethanol (56, 99) , NMDA antagonists were demonstrated to block both learned and unlearned tolerance to chlordiazepoxide. Rats pretreated with MK-801 or ketamine before chlordiazepoxide and returned to their cages exhibited reduced tolerance as compared with control animals (45) . These results would suggest that in addition to the impairment of memory and learning, NMDA antagonists may also influence drug-receptor interaction or effector mechanisms leading to the blockade of tolerance.
Additional evidence for the involvement of NMDA system in the tolerance to benzodiazepine effects comes from a study on the protective effects of lorazepam against pentylenetetrazole convulsions in mice. After 14 d of lorazepam administration complete tolerance to its anticonvulsant effect developed. The concomitant administration of CPP and lorazepam resulted in partial blockade of tolerance to the seizure protective effect of benzodiazepines (61) . Chronic administration of lorazepam caused a significant reduction in in vivo binding of [ 3 H]flumazenil in cerebellum, hippocampus and hypothalamus. This reduction was not affected by the simultaneous treatment with CPP, suggesting that the behavioral effect of the NMDA antagonist was not directly related to the downregulation of benzodiazepine receptors (61).
Marin et al. (74) investigated the hippocampal synaptic plasticity during the development of rapid benzodiazepine tolerance. At the third and fourth days of treatment with diazepam, the tolerance to the reduction in locomotor activity of rats was developed. In hippocampal slices obtained from these rats, increased synaptic plasticity, assessed by the lower threshold needed to induce long term potentiation, was observed. The authors suggested that these findings were in agreement with the hypothesis proposing that NMDA receptors participate in learned tolerance (50) . Khanna et al. (46) investigated the influence of the NMDA system on the development of tolerance to barbiturates. Ketamine and MK-801 pretreatment prevented the development of rapid tolerance to barbital-, pentobarbital-, and phenobarbital-induced motor impairment in rats. These effects were probably independent of pharmacokinetic mechanisms, since previous investigation failed to show any pharmacokinetic basis for rapid tolerance (50, 59) , and because there is no evidence in the literature of any effect of MK-801 on the cytochrome P-450 system (46) . In this study the blockade of tolerance by the NMDA antagonists was consistent with the hypothesis that the NMDA receptor is involved in a learned component of tolerance. Tolerance to pentobarbital on day 2 could be produced by both learning and non-learning paradigms. It is noteworthy that NMDA antagonists blocked tolerance only in the learning paradigms, but not tolerance produced in the non-learning paradigm. Oh et al. (83) reported increased [ 3 H]MK-801 binding in brain regions of pentobarbital-dependent rats and suggested the participation of the NMDA system in physical dependence on pentobarbital.
NMDA AND BARBITURATE TOLERANCE

NMDA AND OPIOID TOLERANCE
Tolerance to the analgesic effect of morphine and other opioids is an important issue for the treatment of pain, since increasing doses of the opioids have to be used to ensure the same effect obtained previously. Just like to ethanol, tolerance to opioids involves both associative and non-associative mechanisms (4, 71) . The development of tolerance to opioids appears to involve several neurotransmitters (3, 7, 70, 75) . The precise molecular mechanisms underlying tolerance to opioids are not fully understood. The opiate binding sites are differentially distributed in the nervous system and the determination of their location, sites of action, anatomical and functional implications has been the focus of interest of many groups (70, 86, 91, 102) .
The opioid receptors belong to a family of receptors that interact with GTP-binding proteins (G proteins) to regulate second messenger systems or ion channels (92) . Several studies suggest that opiates appear to produce their actions by interacting at three major types of receptors, namely µ, δ, and κ (25, 35, 110) . Three distinct families of endogenous opioid peptides have been characterized, the endorphins, enkephalins, and dynorphins (84) . They have been implicated in several aspects including regulation of pain, mental diseases, alcoholism, immunity, reward, and release of neurotransmitters (13, 24, 65, 96) .
In recent years, the development of tolerance to the opioids has been shown to be influenced by NMDA antagonists. Initial studies provided evidence that administration of kynurenic acid or MK-801 prior to morphine, given in doses that do not reduce morphine analgesia, attenuated morphine tolerance measured in rats submitted to the hot-plate test (72) . Similarly, it was shown that MK-801 administered before chronic morphine injections interfered with the development of tolerance and dependence, suggesting that the NMDA system is involved in the neural adaptive processes produced by repeated morphine injections (105) . However, Marek et al. (73) showed that MK-801 administered 2 h after chronic morphine treatment also blocked the development of tolerance. They suggested that chronic morphine treatment results in overactivation of the NMDA system, leading to changes in pain inhibitory system. Possibly the NMDA antagonists block this overactivation. On the other hand, chronic treatment with morphine results in tolerance along with downregulation of [ 3 H]MK-801 in the cortex (30) .
Using a model in which the associative learning was minimized (i.e., sustained release preparation containing MK-801 and morphine), it was shown that MK-801 blocked the development of non-associative long-lasting tolerance to analgesic effect of morphine (6) . In other studies, LY274614 [(±)-6-phosphonomethyl-decahydroisoquinolin-3-carboxylic acid], a competitive NMDA receptor antagonist, was reported to reverse the development of morphine tolerance without reducing the analgesic response (104) . Additional support for these results came from studies showing that MK-801 inhibited tolerance in a preparation devoid of supraspinal input (32, 106) . Moreover, the associative and non-associative forms of tolerance appear to be differentially mediated at the level of the spinal cord, and the NMDA system plays a role in the expression of non-associative tolerance to analgesic effect of morphine (29) . It is also noteworthy that the non-competitive NMDA antagonist MK-801, administered 1 h after a stressful stimulus, blocked the development of tolerance to stress-induced analgesia in mice submitted to the hot plate test (111) .
In other studies, MK-801 and the NMDA receptor/glycine site antagonist ACEA-1328 (5-nitro-6,7-dimethyl-1,4-dihydro-2,3-quinoxalinedione) clearly blocked the development of tolerance to antinociception induced by morphine in CD-1 mice tested in the tail-flick test, without altering the effects in control groups (69) . Studies have also shown that the NMDA receptor antagonists block the development of tolerance to µ-and δ-opioid agonists (8) (9) (10) 27) . Studies by Wong et al. (114) revealed that tolerance to the analgesic effect of morphine was prevented by MK-801, and that this drug prevented the reduction of µ-opioid receptor high-affinity sites observed in tolerant rats that received morphine infusions. Using hippocampal slices, it was shown that morphine tolerance involves arginine vasopressin, NMDA receptors and κ-opioid receptors (98) . These authors suggested that the influence of the NMDA system on opioid tolerance occurs at different levels of the central nervous system and involves distinct mechanisms.
NMDA AND TOLERANCE TO OTHER DRUGS
Continued administration of central stimulants such as amphetamines and cocaine results in tolerance but when used repeatedly these drugs can produce sensitization (89) . Administration of NMDA antagonists have been reported to block the development of sensitization to amphetamine and cocaine (17, 43) . In another study, the effect of MK-801 was tested in two different experimental paradigms. Cocaine (10 and 40 mg/kg) was administered to rats for 3 or 7 d, respectively. The lower dose of cocaine was able to induce tolerance to the increased locomotor activity, whereas the higher dose produced behavioral sensitization. In this study, the participation of NMDA receptor was investigated and it was shown that MK-801 prevented the development of both tolerance and sensitization induced by repeated cocaine administration (18) .
SUMMARY AND CONCLUSION
Tolerance to ethanol and other drugs has been extensively studied over many years. Research during the past two decades has shown that tolerance is a complex phenomenon and cannot be explained solely in terms of interaction between a drug and its target sites. It appears that behavioral and environmental factors play a very important role in the development of tolerance under certain circumstances. Based on the temporal framework of development, tolerance is divided into three different types: chronic, acute, and rapid.
NMDA receptors have been implicated in various brain functions such as learning, memory, ingestion, epileptic seizures and neuronal death. Since NMDA receptors have been strongly implicated in learning and memory and acquisition of drug tolerance shares many characteristics with learning, we hypothesized that the acquisition of drug tolerance should similarly be affected by NMDA antagonists. Indeed, various investigators reported that NMDA antagonists blocked tolerance to a variety of CNS depressants such as ethanol, benzodiazepines, barbiturates or opioids. In other studies, NMDA antagonists blocked tolerance as well as sensitization to CNS stimulants.
Numerous studies with ethanol show that NMDA antagonists blocked tolerance only in the learning paradigm but not tolerance produced in the non-learning paradigm. Similarly, NMDA antagonists blocked learned rapid tolerance to barbiturates but fail to block unlearned rapid tolerance. However, findings in two ethanol studies and numerous studies with benzodiazepines and opioids have demonstrated that NMDA antagonists blocked both learned and unlearned tolerance. Additional studies with different NMDA antago-
